SCHEMBL10075763

SCHEMBL10075763

CSc1cc(Sc2ccc(OCCO)cc2)ccc1C(=O)/C(C)=N/OC(C)=O

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
MAPT P10636 4/20 0.33
HPGD P15428 3/20 0.33
LMNA P02545 3/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
GAA P10253 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LSS P48449 1/20 0.31
CYP3A4 P08684 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
ALDH1A1 P00352 1/20 0.30
NR1I2 O75469 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20709729 0.91 THRA (0.36) THRATHRBSMN1; SMN2MAPTHPGD
SCHEMBL10075781 0.91 SMN1; SMN2 (0.32) SMN1; SMN2HPGDLMNAGAANPSR1
SCHEMBL10075731 0.87 GAA (0.35) THRBSMN1; SMN2MAPTHPGDLMNA
SCHEMBL10075784 0.87 PPARD (0.37) SMN1; SMN2LMNAGAACYP3A4
SCHEMBL10075766 0.85 KDM4E (0.36) SMN1; SMN2MAPTHPGDLMNANPC1
SCHEMBL29394644 0.84 GAA (0.39) MAPTLMNAGAAALDH1A1
SCHEMBL10075739 0.84 GAA (0.39) MAPTLMNAGAAALDH1A1
SCHEMBL10075773 0.83 MAPT (0.32) SMN1; SMN2MAPTHPGDLMNANPC1
SCHEMBL10075786 0.83 SLC6A2 (0.31) SMN1; SMN2GAA
SCHEMBL22639048 0.82 GAA (0.43) THRBSMN1; SMN2MAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2586827-B1 CURABLE RESIN COMPOSITION ADEKA CORP (JP) 2017-12-27 EP disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
EP-2586827-A1 CURABLE RESIN COMPOSITION Adeka Corporation (JP) 2013-05-01 EP disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
EP-2327689-B1 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORP (JP) 2012-02-29 EP disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
EP-2327689-A1 Oxime ester compound and photopolymerization initiator containing the same Adeka Corporation (JP) 2011-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME OXER1, OR10J3, CDK11B THRA 1060/4885THRB 1132/4885SMN1; SMN2 3776/4885
US-20120115972-A1 CURING RESIN COMPOSITION LTA, LOXL1, PLOD2 THRA 2496/4885THRB 3115/4885SMN1; SMN2 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.